Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma
Aim Hepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS). MicroRNAs (miRNAs) play critical roles in HCC initiation, progression, and metastasis and are highly correlated with patient prognosis. Thus, m...
Saved in:
Published in | Hepatology research Vol. 50; no. 10; pp. 1151 - 1163 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc
01.10.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim
Hepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS). MicroRNAs (miRNAs) play critical roles in HCC initiation, progression, and metastasis and are highly correlated with patient prognosis. Thus, miRNA‐based risk signatures and nomograms are urgently required for predicting OS in patients with HCC.
Methods
We constructed a 13‐miRNA‐based signature and prognostic nomogram using 408 HCC samples and 58 normal tissues with miRNA sequencing data and clinical data from 323 patients downloaded from The Cancer Genome Atlas. A total of 195 patients were assigned as the internal validation cohort for verification and testing. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was applied to investigate pathway enrichment for the signature.
Results
We identified and validated a 13‐miRNA risk signature highly associating with the OS of HCC patients. The signature showed good performances by calculating C‐index, area under the curve, and calibration curves. After verification and testing using an internal validation cohort, the results yielded a miRNA‐based signature and a prognostic nomogram with reliable predictive accuracy. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis indicated that various genes and multiple pathways were closely related to the mechanisms of HCC proliferation and metastasis.
Conclusion
We successfully identified a 13‐miRNA‐based signature and prognostic nomogram that are capable of predicting OS in patients with HCC. |
---|---|
AbstractList | AimHepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS). MicroRNAs (miRNAs) play critical roles in HCC initiation, progression, and metastasis and are highly correlated with patient prognosis. Thus, miRNA‐based risk signatures and nomograms are urgently required for predicting OS in patients with HCC.MethodsWe constructed a 13‐miRNA‐based signature and prognostic nomogram using 408 HCC samples and 58 normal tissues with miRNA sequencing data and clinical data from 323 patients downloaded from The Cancer Genome Atlas. A total of 195 patients were assigned as the internal validation cohort for verification and testing. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was applied to investigate pathway enrichment for the signature.ResultsWe identified and validated a 13‐miRNA risk signature highly associating with the OS of HCC patients. The signature showed good performances by calculating C‐index, area under the curve, and calibration curves. After verification and testing using an internal validation cohort, the results yielded a miRNA‐based signature and a prognostic nomogram with reliable predictive accuracy. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis indicated that various genes and multiple pathways were closely related to the mechanisms of HCC proliferation and metastasis.ConclusionWe successfully identified a 13‐miRNA‐based signature and prognostic nomogram that are capable of predicting OS in patients with HCC. Hepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS). MicroRNAs (miRNAs) play critical roles in HCC initiation, progression, and metastasis and are highly correlated with patient prognosis. Thus, miRNA-based risk signatures and nomograms are urgently required for predicting OS in patients with HCC.AIMHepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS). MicroRNAs (miRNAs) play critical roles in HCC initiation, progression, and metastasis and are highly correlated with patient prognosis. Thus, miRNA-based risk signatures and nomograms are urgently required for predicting OS in patients with HCC.We constructed a 13-miRNA-based signature and prognostic nomogram using 408 HCC samples and 58 normal tissues with miRNA sequencing data and clinical data from 323 patients downloaded from The Cancer Genome Atlas. A total of 195 patients were assigned as the internal validation cohort for verification and testing. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was applied to investigate pathway enrichment for the signature.METHODSWe constructed a 13-miRNA-based signature and prognostic nomogram using 408 HCC samples and 58 normal tissues with miRNA sequencing data and clinical data from 323 patients downloaded from The Cancer Genome Atlas. A total of 195 patients were assigned as the internal validation cohort for verification and testing. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was applied to investigate pathway enrichment for the signature.We identified and validated a 13-miRNA risk signature highly associating with the OS of HCC patients. The signature showed good performances by calculating C-index, area under the curve, and calibration curves. After verification and testing using an internal validation cohort, the results yielded a miRNA-based signature and a prognostic nomogram with reliable predictive accuracy. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis indicated that various genes and multiple pathways were closely related to the mechanisms of HCC proliferation and metastasis.RESULTSWe identified and validated a 13-miRNA risk signature highly associating with the OS of HCC patients. The signature showed good performances by calculating C-index, area under the curve, and calibration curves. After verification and testing using an internal validation cohort, the results yielded a miRNA-based signature and a prognostic nomogram with reliable predictive accuracy. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis indicated that various genes and multiple pathways were closely related to the mechanisms of HCC proliferation and metastasis.We successfully identified a 13-miRNA-based signature and prognostic nomogram that are capable of predicting OS in patients with HCC.CONCLUSIONWe successfully identified a 13-miRNA-based signature and prognostic nomogram that are capable of predicting OS in patients with HCC. Aim Hepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS). MicroRNAs (miRNAs) play critical roles in HCC initiation, progression, and metastasis and are highly correlated with patient prognosis. Thus, miRNA‐based risk signatures and nomograms are urgently required for predicting OS in patients with HCC. Methods We constructed a 13‐miRNA‐based signature and prognostic nomogram using 408 HCC samples and 58 normal tissues with miRNA sequencing data and clinical data from 323 patients downloaded from The Cancer Genome Atlas. A total of 195 patients were assigned as the internal validation cohort for verification and testing. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was applied to investigate pathway enrichment for the signature. Results We identified and validated a 13‐miRNA risk signature highly associating with the OS of HCC patients. The signature showed good performances by calculating C‐index, area under the curve, and calibration curves. After verification and testing using an internal validation cohort, the results yielded a miRNA‐based signature and a prognostic nomogram with reliable predictive accuracy. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis indicated that various genes and multiple pathways were closely related to the mechanisms of HCC proliferation and metastasis. Conclusion We successfully identified a 13‐miRNA‐based signature and prognostic nomogram that are capable of predicting OS in patients with HCC. |
Author | Liu, Yufeng Nie, Kechao Yan, Yanhua Jiang, Xiaotao Liu, Fengbin Chen, Xu Li, Peiwu Pan, Jinglin Jiang, Kailin Tang, Shuting Liu, Peng Zheng, Zhihua Lan, Shaoyang Wen, Yi |
Author_xml | – sequence: 1 givenname: Zhihua surname: Zheng fullname: Zheng, Zhihua organization: Guangzhou University of Chinese Medicine – sequence: 2 givenname: Yi surname: Wen fullname: Wen, Yi organization: Guangzhou University of Chinese Medicine – sequence: 3 givenname: Kechao surname: Nie fullname: Nie, Kechao organization: Guangzhou University of Chinese Medicine – sequence: 4 givenname: Shuting surname: Tang fullname: Tang, Shuting organization: Guangzhou University of Chinese Medicine – sequence: 5 givenname: Xu surname: Chen fullname: Chen, Xu organization: The first Affiliated Hospital of Guangzhou University of Chinese Medicine – sequence: 6 givenname: Shaoyang surname: Lan fullname: Lan, Shaoyang organization: The first Affiliated Hospital of Guangzhou University of Chinese Medicine – sequence: 7 givenname: Jinglin surname: Pan fullname: Pan, Jinglin organization: The Hainan Hospital of Chinese Medicine – sequence: 8 givenname: Kailin surname: Jiang fullname: Jiang, Kailin organization: Guangzhou University of Chinese Medicine – sequence: 9 givenname: Xiaotao surname: Jiang fullname: Jiang, Xiaotao organization: Guangzhou University of Chinese Medicine – sequence: 10 givenname: Peng surname: Liu fullname: Liu, Peng organization: Guangzhou University of Chinese Medicine – sequence: 11 givenname: Yanhua surname: Yan fullname: Yan, Yanhua organization: Guangzhou University of Chinese Medicine – sequence: 12 givenname: Fengbin surname: Liu fullname: Liu, Fengbin organization: The first Affiliated Hospital of Guangzhou University of Chinese Medicine – sequence: 13 givenname: Yufeng surname: Liu fullname: Liu, Yufeng organization: Guangzhou University of Chinese Medicine – sequence: 14 givenname: Peiwu surname: Li fullname: Li, Peiwu email: doctorlipw@gzucm.edu.cn, wenrenly2008@163.com organization: The first Affiliated Hospital of Guangzhou University of Chinese Medicine |
BookMark | eNp9kdFKHDEYhUNRqKve9AkCvSmFsclkJslcLotWQdoiCt4N_2QyaySTbJPMLnvXRxB8Q5-kWbdXUsxNfsJ3DufPmaED551G6BMlZzSfbw96Fc4oq5n8gI6oFGVBWHV_kGcmecFZxT-iWYyPhFBByuoIPS-8iylMKhnvsB8wYMpe_jyNRgV_82Oexw6i7nE0SwdpChqD6_Eq-KXzMRmFnR_9MsCIBx_yu-5N9nJL7Nc6gLU4TmFt1mCxcXgFyWiXIt6Y9IBzWEheaWsnCwErCMpkNzhBhwPYqE__3cfo7uL8dnFZXP_8frWYXxeK1VIWwCXjohGqqrpe9rypRJn3kkA1l52ou07pctAlb7qaDKwpCTSCDrwRlRKEKXaMvux98za_Jx1TO5q4iwNO-ym2ZUVrySQRNKOf36CPfgoup8tUTTkhnLNMfd1T-e9iDHpoV8GMELYtJe2un3bXT_vaT4bJG1iZBLsaUgBj_y-he8nGWL19x7y9PP91s9f8BW2cqVE |
CitedBy_id | crossref_primary_10_1186_s12864_020_07104_w crossref_primary_10_1007_s10528_023_10539_x crossref_primary_10_1111_hepr_13719 crossref_primary_10_1111_hepr_13829 crossref_primary_10_3390_ijms21197251 crossref_primary_10_3389_fonc_2020_597996 crossref_primary_10_1042_BSR20204219 crossref_primary_10_1016_j_heliyon_2024_e29326 crossref_primary_10_1111_hepr_13674 |
Cites_doi | 10.1016/j.ymthe.2019.11.021 10.1016/j.omtn.2019.12.043 10.1016/j.jconrel.2019.11.010 10.1186/s12920-019-0586-4 10.1111/apt.14801 10.2147/OTT.S224527 10.7150/thno.41365 10.1080/14656566.2018.1534956 10.1186/s13046-019-1419-1 10.1016/j.bbrc.2019.10.139 10.1053/j.gastro.2017.06.007 10.7150/thno.32543 10.1053/j.gastro.2019.02.038 10.1038/nrd2926 10.3390/cancers11111773 10.1038/nature06174 10.1111/hepr.13338 10.3322/caac.21492 10.1128/MCB.02005-06 10.1007/s12072-017-9807-0 10.3390/cancers12040823 10.1016/j.jare.2019.12.002 10.1186/s13046-019-1480-9 10.1080/14740338.2018.1530212 10.1158/0008-5472.CAN-05-0298 10.3892/ijo.2016.3503 10.1111/hepr.13344 10.1016/j.cell.2017.05.035 10.3390/cells8121560 10.1080/17474124.2017.1294485 10.1038/bjc.2015.170 10.3390/jcm9010281 10.1016/j.phrs.2020.104800 10.1111/apt.15499 10.1007/978-1-4939-6524-3_1 10.1016/j.bbrc.2018.04.041 10.1038/nrclinonc.2017.70 10.1016/j.gene.2019.144159 10.1002/hep.26315 10.1111/1440-1681.13218 |
ContentType | Journal Article |
Copyright | 2020 The Japan Society of Hepatology 2020 The Japan Society of Hepatology. |
Copyright_xml | – notice: 2020 The Japan Society of Hepatology – notice: 2020 The Japan Society of Hepatology. |
DBID | AAYXX CITATION 7T5 7TM 7U9 H94 7X8 |
DOI | 10.1111/hepr.13538 |
DatabaseName | CrossRef Immunology Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1872-034X |
EndPage | 1163 |
ExternalDocumentID | 10_1111_hepr_13538 HEPR13538 |
Genre | article |
GrantInformation_xml | – fundername: Major research project of Guangzhou University of Chinese medicine, China (2019) funderid: No.A1‐2606‐19‐110‐007 – fundername: The first affiliated hospital of Guangzhou University of Chinese medicine “innovation foster hospital” clinical research project, China (2019) funderid: No.2019IIT19 – fundername: The first affiliated hospital of Guangzhou University of Chinese medicine “innovation foster hospital” innovation research team project, China (2017) funderid: No.2017TD05 – fundername: Guangdong natural science foundation (PhD) project, China (2017) funderid: No.2017A030310121 – fundername: The first affiliated hospital of Guangzhou University of Chinese medicine “innovation foster hospital” Youth scientific research talent training program, China (2015) funderid: No.2015QN09 – fundername: Guangdong natural science fund project, China (2019) funderid: No.2019A1515011145 |
GroupedDBID | --- --K .3N .GA .Y3 05W 0R~ 10A 1B1 1OC 1~5 29I 31~ 33P 3SF 4.4 4G. 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AAHQN AAIPD AALRI AAMNL AANHP AANLZ AAONW AAQFI AAQXK AASGY AAXRX AAXUO AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABIJN ABJNI ABPVW ABQWH ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIUM ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITUG AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD ESX EX3 F00 F01 F04 F5P FDB FEDTE FGOYB FUBAC G-Q G-S G.N GODZA H.X HF~ HGLYW HVGLF HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NQ- O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K R2- RIG ROL RPZ RX1 SEW SSZ SUPJJ TEORI TUS UB1 UHS V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 ZZTAW ~IA ~WT AAYXX ACVFH ADCNI AEUPX AEYWJ AFPUW AGHNM AGQPQ AGYGG AIGII CITATION 7T5 7TM 7U9 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 7X8 |
ID | FETCH-LOGICAL-c3588-a6836797c44bd8d694720018a1e68b75bbce2fe269b50f3920a971f6974c703c3 |
IEDL.DBID | DR2 |
ISSN | 1386-6346 |
IngestDate | Fri Jul 11 17:01:46 EDT 2025 Fri Jul 25 05:15:54 EDT 2025 Tue Jul 01 01:58:22 EDT 2025 Thu Apr 24 23:00:25 EDT 2025 Wed Jan 22 16:59:53 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3588-a6836797c44bd8d694720018a1e68b75bbce2fe269b50f3920a971f6974c703c3 |
Notes | The authors have no conflict of interest. Conflict of interest Zhihua Zheng, Yi Wen, and Kecao Nie contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PQID | 2451600663 |
PQPubID | 2045151 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2415838071 proquest_journals_2451600663 crossref_primary_10_1111_hepr_13538 crossref_citationtrail_10_1111_hepr_13538 wiley_primary_10_1111_hepr_13538_HEPR13538 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2020 2020-10-00 20201001 |
PublicationDateYYYYMMDD | 2020-10-01 |
PublicationDate_xml | – month: 10 year: 2020 text: October 2020 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken |
PublicationTitle | Hepatology research |
PublicationYear | 2020 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2019; 8 2019; 9 2007; 449 2019; 50 2019; 11 2019; 12 2018; 500 2020; 522 2019; 38 2005; 65 2017; 1509 2019; 18 2020; 12 2018; 109 2017; 153 2020; 10 2016; 17 2020; 725 2018; 48 2020; 19 2018; 68 2018; 19 2018; 17 2013; 58 2017; 14 2015; 113 2017; 11 2020; 9 2020; 28 2019; 49 2019 2020; 47 2009; 8 2020; 22 2020; 157 2019; 316 2018; 12 2016; 49 2017; 169 2019; 156 2007; 27 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 Pei T (e_1_2_9_41_1) 2020; 19 e_1_2_9_15_1 Intaraprasong P (e_1_2_9_7_1) 2016; 17 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 Luk ST (e_1_2_9_45_1) 2019 e_1_2_9_42_1 e_1_2_9_20_1 Tang J (e_1_2_9_38_1) 2018; 109 e_1_2_9_40_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 Song SK (e_1_2_9_27_1) 2019; 18 e_1_2_9_29_1 |
References_xml | – volume: 12 start-page: 56 year: 2018 end-page: 67 article-title: Impact of etiological treatment on prognosis publication-title: Hepatol Int – volume: 65 start-page: 3509 year: 2005 end-page: 3512 article-title: MicroRNA biogenesis and cancer publication-title: Cancer Res – volume: 10 start-page: 3668 year: 2020 end-page: 3683 article-title: miR‐17‐5p and miR‐20a‐5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3‐NF‐κB positive feedback loop publication-title: Theranostics – volume: 68 start-page: 394 year: 2018 end-page: 424 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 38 start-page: 454 year: 2019 article-title: Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma publication-title: J Exp Clin Can Res – volume: 12 start-page: 164 year: 2019 article-title: Integrative molecular analysis of metastatic hepatocellular carcinoma publication-title: BMC Med Genomics – volume: 109 start-page: 15 year: 2018 end-page: 23 article-title: Exosomal miR‐9‐3p suppresses HBGF‐5 expression and is a functional biomarker in hepatocellular carcinoma publication-title: Minerva Med – volume: 449 start-page: 682 year: 2007 end-page: 688 article-title: Tumour invasion and metastasis initiated by microRNA‐10b in breast cancer publication-title: Nature – volume: 522 start-page: 716 year: 2020 end-page: 723 article-title: miR‐1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma publication-title: Biochem Bioph Res Co – volume: 157 year: 2020 article-title: CCL22 signaling contributes to sorafenib resistance in hepatitis B virus‐associated hepatocellular carcinoma publication-title: Pharmacol Res – volume: 19 start-page: 731 year: 2020 end-page: 740 article-title: MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways publication-title: J Hepatol – volume: 12 start-page: 9201 year: 2019 end-page: 9213 article-title: CLK3 is a direct target of miR‐144 and contributes to aggressive progression in hepatocellular carcinoma publication-title: Oncotargets Ther – volume: 19 start-page: 1941 year: 2018 end-page: 1948 article-title: Regorafenib: a promising treatment for hepatocellular carcinoma publication-title: Expert Opin Pharmaco – year: 2019 article-title: Deficiency in embryonic stem cell marker REX1 activates MKK6‐dependent p38 MAPK signaling to drive hepatocarcinogenesis publication-title: Hepatology – volume: 14 start-page: 392 year: 2017 article-title: Immunotherapy: nivolumab keeps HCC in check and opens avenues for checkmate publication-title: Nat Rev Clin Oncol – volume: 28 start-page: 587 year: 2020 end-page: 598 article-title: miR‐639 expression is silenced by DNMT3A‐mediated hypermethylation and functions as a tumor suppressor in liver cancer cells publication-title: Mol Ther – volume: 500 start-page: 211 year: 2018 end-page: 216 article-title: Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR‐767‐3p targeting SET publication-title: Biochem Bioph Res Co – volume: 38 start-page: 489 year: 2019 article-title: Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12‐12HETE‐GPR31 signaling axis publication-title: J Exp Clin Can Res – volume: 19 start-page: 1073 year: 2020 end-page: 1085 article-title: miR‐552 regulates liver tumor‐initiating cell expansion and sorafenib resistance publication-title: Mol Ther Nucleic Acids – volume: 725 year: 2020 article-title: Transcriptional analysis and differentially expressed gene screening of spontaneous liver tumors in CBA/CaJ mice publication-title: Gene – volume: 17 start-page: 3697 year: 2016 end-page: 3703 article-title: Advances in management of hepatocellular carcinoma publication-title: Asian Pac J Cancer Prev – volume: 8 start-page: 1560 year: 2019 article-title: Extracellular vesicles‐encapsulated microRNA‐125b produced in genetically modified mesenchymal stromal cells inhibits hepatocellular carcinoma cell proliferation publication-title: Cells – volume: 316 start-page: 317 year: 2019 end-page: 330 article-title: Encapsulated microRNA by gemcitabine prodrug for cancer treatment publication-title: J Control Release – volume: 48 start-page: 44 year: 2018 end-page: 54 article-title: Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience publication-title: Aliment Pharm Ther – volume: 17 start-page: 1095 year: 2018 end-page: 1105 article-title: Optimal management of patients with hepatocellular carcinoma treated with lenvatinib publication-title: Expert Opin Drug Saf – volume: 49 start-page: 902 year: 2019 end-page: 918 article-title: Long non‐coding RNA miR143HG predicts good prognosis and inhibits tumor multiplication and metastasis by suppressing mitogen‐activated protein kinase and Wnt signaling pathways in hepatocellular carcinoma publication-title: Hepatol Res – volume: 8 start-page: 627 year: 2009 end-page: 644 article-title: Targeting the phosphoinositide 3‐kinase pathway in cancer publication-title: Nat Rev Drug Discov – volume: 156 start-page: 2313 year: 2019 end-page: 2329 article-title: HCV‐induced epigenetic changes associated with liver cancer risk persist after sustained virologic response publication-title: Gastroenterology – volume: 50 start-page: 1037 year: 2019 end-page: 1048 article-title: Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis publication-title: Aliment Pharm Ther – volume: 22 start-page: 57 year: 2020 end-page: 66 article-title: Circulatory miRNA‐484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis publication-title: J Adv Res – volume: 9 start-page: 281 year: 2020 article-title: Serum exosomal microRNA, miR‐10b‐5p, as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma publication-title: J Clin Med – volume: 113 start-page: 252 year: 2015 end-page: 258 article-title: miR‐9‐3p plays a tumour‐suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells publication-title: Brit J Cancer – volume: 49 start-page: 5 year: 2016 end-page: 32 article-title: Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review) publication-title: Int J Oncol – volume: 47 start-page: 485 year: 2020 end-page: 494 article-title: MicroRNA‐627‐5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator publication-title: Clin Exp Pharmacol Physiol – volume: 18 start-page: 6293 year: 2019 end-page: 6303 article-title: MicroRNAs associated with microvascular invasion in hepatocellular carcinoma and their prognostic impacts in patients undergoing hepatic resection publication-title: Oncol Lett – volume: 58 start-page: 205 year: 2013 end-page: 217 article-title: MicroRNA‐140‐5p suppresses tumor growth and metastasis by targeting transforming growth factor‐β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma publication-title: Hepatology (Baltimore) – volume: 12 start-page: 823 year: 2020 article-title: The crosstalk between tumor cells and the microenvironment in hepatocellular carcinoma: the role of exosomal microRNAs and their clinical implications publication-title: Cancers (Basel) – volume: 153 start-page: 812 year: 2017 end-page: 826 article-title: Identification of an immune‐specific class of hepatocellular carcinoma, based on molecular features publication-title: Gastroenterology – volume: 11 start-page: 695 year: 2017 end-page: 701 article-title: Prognostic value of site‐specific extra‐hepatic disease in hepatocellular carcinoma: a SEER database analysis publication-title: Expert Rev Gastroent – volume: 49 start-page: 810 year: 2019 end-page: 822 article-title: Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma publication-title: Hepatol Res – volume: 169 start-page: 1342 year: 2017 end-page: 1356 article-title: Landscape of infiltrating T cells in liver cancer revealed by single‐cell sequencing publication-title: Cell – volume: 1509 start-page: 1 year: 2017 end-page: 10 article-title: MiRNA biogenesis and regulation of diseases: an overview publication-title: Methods Mol Biol – volume: 27 start-page: 2240 year: 2007 end-page: 2252 article-title: Transcripts targeted by the microRNA‐16 family cooperatively regulate cell cycle progression publication-title: Mol Cell Biol – volume: 11 start-page: 1773 year: 2019 article-title: Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct‐acting antivirals publication-title: Cancer – volume: 9 start-page: 4779 year: 2019 end-page: 4794 article-title: The miR‐561‐5p/CXCL1 signaling axis regulates pulmonary metastasis in hepatocellular carcinoma involving CXCR1 natural killer cells infiltration publication-title: Theranostics – ident: e_1_2_9_22_1 doi: 10.1016/j.ymthe.2019.11.021 – ident: e_1_2_9_19_1 doi: 10.1016/j.omtn.2019.12.043 – ident: e_1_2_9_28_1 doi: 10.1016/j.jconrel.2019.11.010 – ident: e_1_2_9_46_1 doi: 10.1186/s12920-019-0586-4 – ident: e_1_2_9_33_1 doi: 10.1111/apt.14801 – ident: e_1_2_9_17_1 doi: 10.2147/OTT.S224527 – ident: e_1_2_9_18_1 doi: 10.7150/thno.41365 – ident: e_1_2_9_8_1 doi: 10.1080/14656566.2018.1534956 – ident: e_1_2_9_43_1 doi: 10.1186/s13046-019-1419-1 – ident: e_1_2_9_30_1 doi: 10.1016/j.bbrc.2019.10.139 – ident: e_1_2_9_4_1 doi: 10.1053/j.gastro.2017.06.007 – volume: 17 start-page: 3697 year: 2016 ident: e_1_2_9_7_1 article-title: Advances in management of hepatocellular carcinoma publication-title: Asian Pac J Cancer Prev – ident: e_1_2_9_36_1 doi: 10.7150/thno.32543 – volume: 19 start-page: 731 year: 2020 ident: e_1_2_9_41_1 article-title: MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways publication-title: J Hepatol – ident: e_1_2_9_32_1 doi: 10.1053/j.gastro.2019.02.038 – ident: e_1_2_9_40_1 doi: 10.1038/nrd2926 – ident: e_1_2_9_24_1 doi: 10.3390/cancers11111773 – year: 2019 ident: e_1_2_9_45_1 article-title: Deficiency in embryonic stem cell marker REX1 activates MKK6‐dependent p38 MAPK signaling to drive hepatocarcinogenesis publication-title: Hepatology – ident: e_1_2_9_16_1 doi: 10.1038/nature06174 – volume: 109 start-page: 15 year: 2018 ident: e_1_2_9_38_1 article-title: Exosomal miR‐9‐3p suppresses HBGF‐5 expression and is a functional biomarker in hepatocellular carcinoma publication-title: Minerva Med – ident: e_1_2_9_25_1 doi: 10.1111/hepr.13338 – ident: e_1_2_9_2_1 doi: 10.3322/caac.21492 – ident: e_1_2_9_15_1 doi: 10.1128/MCB.02005-06 – ident: e_1_2_9_35_1 doi: 10.1007/s12072-017-9807-0 – ident: e_1_2_9_12_1 doi: 10.3390/cancers12040823 – ident: e_1_2_9_21_1 doi: 10.1016/j.jare.2019.12.002 – ident: e_1_2_9_42_1 doi: 10.1186/s13046-019-1480-9 – ident: e_1_2_9_10_1 doi: 10.1080/14740338.2018.1530212 – ident: e_1_2_9_11_1 doi: 10.1158/0008-5472.CAN-05-0298 – ident: e_1_2_9_13_1 doi: 10.3892/ijo.2016.3503 – ident: e_1_2_9_26_1 doi: 10.1111/hepr.13344 – ident: e_1_2_9_3_1 doi: 10.1016/j.cell.2017.05.035 – ident: e_1_2_9_23_1 doi: 10.3390/cells8121560 – ident: e_1_2_9_6_1 doi: 10.1080/17474124.2017.1294485 – ident: e_1_2_9_39_1 doi: 10.1038/bjc.2015.170 – ident: e_1_2_9_20_1 doi: 10.3390/jcm9010281 – ident: e_1_2_9_31_1 doi: 10.1016/j.phrs.2020.104800 – ident: e_1_2_9_34_1 doi: 10.1111/apt.15499 – ident: e_1_2_9_14_1 doi: 10.1007/978-1-4939-6524-3_1 – ident: e_1_2_9_37_1 doi: 10.1016/j.bbrc.2018.04.041 – ident: e_1_2_9_9_1 doi: 10.1038/nrclinonc.2017.70 – ident: e_1_2_9_44_1 doi: 10.1016/j.gene.2019.144159 – ident: e_1_2_9_5_1 doi: 10.1002/hep.26315 – ident: e_1_2_9_29_1 doi: 10.1111/1440-1681.13218 – volume: 18 start-page: 6293 year: 2019 ident: e_1_2_9_27_1 article-title: MicroRNAs associated with microvascular invasion in hepatocellular carcinoma and their prognostic impacts in patients undergoing hepatic resection publication-title: Oncol Lett |
SSID | ssj0017024 |
Score | 2.310416 |
Snippet | Aim
Hepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS).... AimHepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS).... Hepatocellular carcinoma (HCC) is a common malignancy associated with a poor prognosis due to difficulties in reliably estimating overall survival (OS).... |
SourceID | proquest crossref wiley |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 1151 |
SubjectTerms | Genes Genomes Hepatocellular carcinoma Liver cancer Malignancy Medical prognosis Metastases Metastasis microRNA MicroRNAs miRNA miRNA‐based risk signature Ontology overall survival Prognosis prognostic nomogram Survival |
Title | Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhepr.13538 https://www.proquest.com/docview/2451600663 https://www.proquest.com/docview/2415838071 |
Volume | 50 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6WHEIvTdIH3SYNE5pLCw5-yLINvYSQsAQ2lCWBvRSjl2nJxg717iWn_IRA_mF_SWe09m5aSqG9GVuWZWlG-iR9-gbgMHO5KWLm6dBYHAgCIEFhEhlomm6FVWWU9SSa8YUcXYnzaTodwKf-LMxSH2K14Mae4ftrdnCl2ydO_tXdfvdRG_ikL5O1GBFNVtpRURZ2EW1zGchEyE6blGk861d_HY3WEPMpUPUjzdkWfOnLuCSYXB8t5vrI3P0m3_i_P7ENzzsIisdLm9mBgatfwOa422R_CY8cxLOXlcWmQoVR8uP-4Ya5e5OLY7rksc8icz-8Liiq2iIzveqGZZ-xbm486wsJEdN9zpnZ1ch0UTWbYbugDopMHL_V2Am7tsgrwkglVfOGdxOYHouGIx1RbuoVXJ2dXp6Mgi52Q2CSlJxPyTyRWZEZIbTNrSxExuytXEVO5jpLtTYurlwsC52GFYG0UBVZVEma3hjqhEzyGjbqpnZvAMlqnBGpNdImInYEaVInTV5Za_NIWDuED30blqYTNuf4GrOyn-BwLZe-lofwfpX2dinn8cdUe70plJ1Lt2XMIY09QhvCweoxOSPXiapds-A0EW9DE2wbwkff7n_5Sjk6_TzxV2__JfEuPIt5zu8JhXuwQfbg3hEwmut97wA_AWpQDkA |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB21VKJcoC0gtqXtVOUCUtAmcRzniBBo27KragUSt8ixHbViSVB399JTfwIS_5Bf0hmvd6GoQmpvUeJ8OTP2s_3yHsBO7pQpEubpUF8cCQIgUWFSGVU03OrWtdHWk2j6A9k7E5_Ps_PAzeF_YWb6EIsJN84M315zgvOE9L0s_-aufnjbBvUUnrGltx9RDRfqUXHeDZ62SkYyFTKokzKR5-7cP_ujO5B5H6r6vuZ4bWaoOvYShUwxudifTqp98_OBgON_v8YLWA0oFA9mYfMSnrjmFSz3wzr7Otywj-dcWRbbGjXG6e2v60um7w0HB7TJ3Z9Fpn94aVDUjUUmezUtKz9j01564hcSKKb9fGUmWCMzRvVohOMptVEU5fi9waDtOkaeFEZ6Uj1peUGBGbJo2OyIrqY34Oz46PSwFwX7hsikGeWfliqVeZEbISqrrCxEzgQupWMnVZVnVWVcUrtEFlXWrQmndXWRx7WkEY6hdsikm7DUtI3bAqTAcUZk1kibisQRqsmcNKq21qpYWNuB3flHLE3QNmeLjVE5H-NwLZe-ljvwcVH2aqbo8ddS2_NYKENWj8uEXY09SOvAh8VhykeuE924dsplYl6JJuTWgT3_4R-5S9k7-jr0W6__pfB7eN477Z-UJ58GX97ASsJTAJ5fuA1LFBvuLeGkSfXOZ8NvK70SWw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VVqq4UFpALBSYCi4gpcqH4zgSl4p2tdB2Va2o1AuKHNsRiG2yYncvPfUnVOIf8kuY8SbbgiqkcrMSx3HsGfvZfnkD8CZzyuQx83RoLg4EAZAgN4kMSlpuhVVltPUkmuOhHJyKT2fp2Qq87_6FWehDLDfc2DP8eM0OPrHVDSf_6iY_fNQGdQ_WhAwV2_T-aCkeFWVhG9JWyUAmQrbipMzjuX72z-noGmPeRKp-qulvwJeukguGyffd-azcNRd_6Tf-71c8hActBsW9hdFswoqrt2D9uD1lfwQ_OYpnpyuLTYUao-TX5dU5k_dGwz1K8uRnkckfXhgUdW2RqV51w7rPWDfnnvaFBInpOpfM9Gpkvqgej3E6pxGKbBy_1dgqu06Rt4SRaqpnDR8nMD8WDYc6otL0YzjtH3z-MAja4A2BSVLyPi1VIrM8M0KUVlmZi4zpW0pHTqoyS8vSuLhysczLNKwIpYU6z6JK0vrG0ChkkiewWje1ewpIZuOMSK2RNhGxI0yTOmlUZa1VkbC2B2-7PixMq2zOATbGRbfC4VYufCv34PUy72Sh53Frru3OFIrWp6dFzDGNPUTrwc7yNnkjt4muXTPnPBGfQxNu68E73-__eEsxODgZ-dSzu2R-Besn-_3i6OPw8Dncj3n978mF27BKpuFeEEialS-9L_wGFAoREw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Construction+of+a+13%E2%80%90microRNA%E2%80%90based+signature+and+prognostic+nomogram+for+predicting+overall+survival+in+patients+with+hepatocellular+carcinoma&rft.jtitle=Hepatology+research&rft.au=Zheng%2C+Zhihua&rft.au=Wen%2C+Yi&rft.au=Nie%2C+Kechao&rft.au=Tang%2C+Shuting&rft.date=2020-10-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1386-6346&rft.eissn=1872-034X&rft.volume=50&rft.issue=10&rft.spage=1151&rft.epage=1163&rft_id=info:doi/10.1111%2Fhepr.13538&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6346&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6346&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6346&client=summon |